Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Pyxis Oncology, Inc. | 45,867 | reported | 24 Mar 2026 | tx 4+158,606 |
| Acrivon Therapeutics, Inc. | 9,366 | reported | 18 May 2026 | tx 3+62,141 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 18 May 2026 | GRANT_AWARD | Acrivon Therapeutics, Inc. | 9,366 | 0.00 USD | |
| 24 Mar 2026 | GRANT_AWARD | Pyxis Oncology, Inc. | 45,867 | 0.00 USD | deriv |
| 13 Jun 2025 | GRANT_AWARD | Acrivon Therapeutics, Inc. | 20,275 | 0.00 USD | deriv |
| 31 Mar 2025 | GRANT_AWARD | Pyxis Oncology, Inc. | 36,979 | 0.98 USD | deriv |
| 07 Jun 2024 | GRANT_AWARD | Pyxis Oncology, Inc. | 6,000 | 0.00 USD | |
| 12 Mar 2024 | GRANT_AWARD | Pyxis Oncology, Inc. | 69,760 | 0.00 USD | deriv |
| 04 Mar 2024 | GRANT_AWARD | Acrivon Therapeutics, Inc. | 32,500 | 0.00 USD | deriv |